Turner William D. 4

What Happened

• William D. Turner, Chief Regulatory Officer of Vera Therapeutics (VERA), was granted equity awards on 2026-02-04: 25,000 restricted stock units (RSUs) and a 50,000-share derivative award (stock option/award). Both were reported as acquired at $0.00 (standard compensation grants), totaling 75,000 potential shares.

Key Details

• Transaction date: 2026-02-04. Form 4 filed: 2026-02-06.
• Price: $0.00 per share (award/grant — compensation, not an open-market purchase).
• Shares acquired: 25,000 RSUs (non-derivative) + 50,000 derivative award (option/award) = 75,000 potential shares.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes:
  • F1: The 25,000 RSUs vest 25% on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continued service.
  • F2: The 50,000 derivative award vests 1/48th on March 4, 2026 and 1/48th monthly thereafter, subject to continued service.
• Filing timeliness: No late-filing flag indicated in the supplied data.

Context

• These entries are compensation grants (awards), not purchases or sales — common for employee compensation and not a direct market signal of buying or selling.
• The 50,000-share item is a derivative award (vesting schedule described above); it does not mean immediate ownership of all shares until vested/exercised.
• No indication in the filing that any shares were sold immediately (no cashless exercise or market sale reported).